MedPath

Theophylline

Generic Name
Theophylline
Brand Names
Elixophyllin, Elixophylline, Pulmophylline, Quibron-T, Theo-24, Theolair, Uniphyl
Drug Type
Small Molecule
Chemical Formula
C7H8N4O2
CAS Number
58-55-9
Unique Ingredient Identifier
0I55128JYK
Background

A methylxanthine derivative from tea with diuretic, smooth muscle relaxant, bronchial dilation, cardiac and central nervous system stimulant activities. Mechanistically, theophylline acts as a phosphodiesterase inhibitor, adenosine receptor blocker, and histone deacetylase activator. Theophylline is marketed under several brand names such as Uniphyl and Theochron, and it is indicated mainly for asthma, bronchospasm, and COPD.

Indication

For the treatment of the symptoms and reversible airflow obstruction associated with chronic asthma and other chronic lung diseases, such as emphysema and chronic bronchitis.

Associated Conditions
Asthma, Bronchitis, Bronchoconstriction, Bronchospasm, Chronic Obstructive Pulmonary Disease (COPD), Chronic bronchial inflammation
Associated Therapies
Airway secretion clearance therapy, Bronchodilation
Clinical Trials
Related News

Medicenna to Present MDNA11 ABILITY-1 Trial Update and Novel MDNA113 Data at AACR 2025

• Medicenna Therapeutics will present interim results from its Phase 1/2 ABILITY-1 trial of MDNA11, the only long-acting 'beta-enhanced not-alpha' IL-2 super-agonist in clinical development for advanced solid tumors. • The company will also showcase preclinical data on MDNA113, a first-in-class tumor-targeted and tumor-activated bifunctional anti-PD1-IL2 Superkine designed to enhance therapeutic efficacy. • Both presentations will take place at the American Association for Cancer Research Annual Meeting in Chicago from April 25-30, 2025, highlighting Medicenna's expanding immunotherapy pipeline.

Aulos Bioscience to Present Promising Phase 2 Data for Novel IL-2 Therapeutic in Melanoma Treatment

• Aulos Bioscience will present new Phase 2 data for AU-007, an AI-designed monoclonal antibody targeting IL-2, showing promising results in second-line melanoma treatment at the upcoming AACR Annual Meeting. • AU-007's unique mechanism prevents IL-2 from binding to regulatory T cells while allowing it to activate effector T cells and NK cells, potentially overcoming limitations of traditional IL-2 therapies. • The novel therapeutic may significantly reduce serious side effects associated with high-dose IL-2 therapy, including vascular leak syndrome and pulmonary edema, by preventing IL-2 binding to CD25-containing receptors.

Cyrano Therapeutics Advances Novel Treatment for Post-Viral Smell Loss with Soft Mist Technology

• Cyrano Therapeutics has completed enrollment of 150 patients in its Phase 2 FLAVOR trial evaluating CYR-064, a potential first-in-class treatment for post-viral smell loss, with data expected in Q4 2025. • The company secured an exclusive license agreement with Resyca for soft mist nasal spray technology designed to enhance drug deposition in the olfactory region, potentially improving therapeutic efficacy. • Post-viral hyposmia affects over 60 million people across the US, Europe, and Japan, with no FDA-approved treatments currently available, representing a significant unmet medical need.

Medicenna Reports 78% Disease Control Rate for MDNA11-KEYTRUDA Combination in Advanced Cancer Trial

• Medicenna's ABILITY-1 trial demonstrates promising results with a 78% disease control rate in the MDNA11-KEYTRUDA combination arm, including complete and partial responses in advanced cancer patients. • The company's MDNA11 monotherapy showed significant efficacy with a 30% objective response rate in checkpoint-resistant patients, highlighting its potential as a standalone treatment. • With $30 million in cash reserves, Medicenna is well-positioned to advance its clinical programs through mid-2026, including completion of MDNA11 trials and development of novel immunotherapy MDNA113.

Novel Nasal Spray CYR-064 Enters Trial for Parkinson's-Related Smell Loss

• Cyrano Therapeutics launches investigator-initiated study of CYR-064 nasal spray to treat hyposmia in Parkinson's disease patients, addressing a common early non-motor symptom. • The 24-week single-arm trial will evaluate 15-20 patients with moderate to severe hyposmia, administering twice-daily doses of CYR-064 through nasal spray delivery. • The study will assess efficacy using multiple measures including the NRS-11 smell scale and Sniffin' Sticks Olfactory Test, with potential implications for improving quality of life in Parkinson's patients.

Medicenna's MDNA11 Shows Promise in Advanced Solid Tumors: Updated Phase 1/2 Data

• Medicenna's MDNA11, an IL-2 Superkine, demonstrates single-agent activity in patients with advanced solid tumors in an ongoing Phase 1/2 ABILITY-1 study. • The ABILITY-1 study evaluates MDNA11 both as a monotherapy and in combination with pembrolizumab for various advanced or metastatic solid tumors. • Updated clinical data, including safety and efficacy results, were presented at the 2024 Immunotherapy Bridge Conference on December 5, 2024. • MDNA11 is engineered to preferentially activate immune effector cells, potentially overcoming limitations of previous IL-2 therapies.

Aulos Bioscience Doses First Patient in Phase 2 NSCLC Trial of AU-007, Avelumab, and Aldesleukin Combination

• Aulos Bioscience has dosed the first patient in a Phase 2 trial evaluating AU-007, avelumab, and low-dose aldesleukin for non-small cell lung cancer (NSCLC). • The trial is a collaboration with Merck KGaA and focuses on second-line treatment for PD-L1+ NSCLC patients who have progressed after first-line checkpoint inhibitor therapy. • Preclinical data showed the combination of AU-007 with avelumab and IL-2 resulted in strong anti-cancer activity, including complete tumor eradication. • Aulos Bioscience plans to share preliminary data from this Phase 2 cohort in the first half of 2025.

ASH 2024: ECOG-ACRIN and PrECOG Present Advances in Leukemia and Lymphoma Treatment

• ECOG-ACRIN and PrECOG will present new data at ASH 2024, highlighting advancements in lymphoma and acute leukemia treatments. • Updated results from the E1910 trial show blinatumomab's benefit in older B-cell ALL patients, reinforcing its role in consolidation therapy. • PrE0905 study indicates gilteritinib leads to higher remission rates than midostaurin in FLT3-mutated AML, though MRD negativity remains similar. • Acalabrutinib's addition or substitution in chemoimmunotherapy for mantle cell lymphoma is explored in the ECOG-ACRIN EA4181 trial.

Aulos Bioscience's AU-007 Shows Promise in Phase 2 Solid Tumor Trial

• Aulos Bioscience is set to present Phase 2 data on AU-007, a novel IL-2 therapeutic antibody, at the SITC 2024 Annual Meeting. • AU-007 uniquely targets the CD25-binding portion of IL-2, enhancing anti-tumor immunity by selectively activating effector T cells and NK cells. • The Phase 2 trial data includes early results in melanoma and renal cell carcinoma, building on previously presented positive clinical data. • AU-007 aims to improve upon traditional IL-2 therapies by reducing immunosuppression and toxicities like vascular leak syndrome.
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy